Open AccessClonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration
Author(s) -
H. Robert Bergen,
Surendra Dasari,
Angela Dispenzieri,
John R. Mills,
Marina Ramı́rez-Alvarado,
Renee C. Tschumper,
Diane F. Jelinek,
David R. Barnidge,
David Murray
Publication year - 2015
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2015.242651
Subject(s) - minimal residual disease , bone marrow , immunoglobulin light chain , multiple myeloma , flow cytometry , medicine , pathology , immunohistochemistry , antibody , microbiology and biotechnology , peptide , chemistry , immunology , biology , biochemistry
Analytically sensitive techniques for measuring minimal residual disease (MRD) in multiple myeloma (MM) currently require invasive and costly bone marrow aspiration. These methods include immunohistochemistry (IHC), flow cytometry, quantitative PCR, and next-generation sequencing. An ideal MM MRD test would be a serum-based test sensitive enough to detect low concentrations of Ig secreted from multifocal lesions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom